Skip to main content

Advertisement

Table 2 Expected annual number of new human papillomavirus (HPV)-related cancer cases in men in Europea

From: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review

Cancer sites (ICD 10 code) Expected number of new cancer cases, irrespective of HPV status (bounds) HPV prevalence by site (%) (95%CI) Expected number of new cancer cases attributable to HPV (bounds) Prevalence of HPV 16/18 in HPV-positive cancers (%) Expected number of new cancer cases attributable to HPV16/18
Head and neck Oral cavityb Oropharynxc Larynx (C32) 67,354 (63,443-71,292) 20,133 (18,768-21,514) 20,433 (19,651-21,776) 26,788 (25,210-28,382) 16.0 (13.4-18.8) 28.2d (24.4-32.2) 21.3 (18.5-24.3) [18] 14,098 (11,455-17,077) 3,221 (2,515-4,045) 5,171 (5030-5311) 5,706 (4,664-6,897) 68.2/34.1 86.7/2.8 69.2/17.0 12,707 3,221 4,567 4,919
Anus (C21) 2,162 (1,722-2,620) 84.2 (81.5-86.9) [19] 1,821 (1,403-2,277) 87.1/6.2 1,699
Penis (C60) 3,178 (2,623-3,751) 46.7 (42.0-51.3) [20] 1,484 (1,102-1925) 60.2/13.4 1,091
Total 72,694 (67,957-77,470)   17,403 (14,049-21,161)   15,497
  1. ICD International Classification of Diseases, CI confidence interval
  2. a 26 European countries
  3. b Includes tongue (C01-02), mouth (C03-06), and also includes base of the tongue, which actually belongs to the oropharynx
  4. c Includes tonsil (C09), other oropharynx (C10), hypopharynx (C12-13) and pharynx unspecified (C14)
  5. d Except hypopharynx (C12-13), where HPV prevalence is the same as in laryngeal cancer (C32)